title: In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
abstract: In this study, we used four human mesothelioma cell lines (M14K, M24K, M25K and M38K), one transformed human mesothelial cell line (MeT-5A) and one primary mesothelial culture (UPL) to test for in vitro sensitivity to docetaxel, paclitaxel, SN-38 [an active metabolite of irinotecan (CPT-11)] and gemcitabine, as single agents. Subconfluent cell cultures were treated with 2x10(-9), 5x10(-9), 10(-8), 2x10(-8) and 5x10(-8) M concentrations of each drug for 48 h. The sensitivity was measured in terms of cell viability using the Trypan blue exclusion method. All four drugs were potent inhibitors of mesothelioma cell growth, but cell lines from different patients diverged in their sensitivity to the individual agents. In most cases docetaxel, paclitaxel and SN-38 were more potent killers of mesothelioma cells than gemcitabine. The induction of DNA damage was investigated using the Comet assay; cells from two cell lines (M14K and M25K) were treated with subtoxic 10(-8) M concentrations of each drug for 4, 24 and 48 h. Each of the agents caused a slight increase in DNA single-strand breaks at a concentration of 10(-8) M.
authors.affiliation: Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, Helsinki. tiina.ollikainen@occuphealth.fi
authors.forename: T
authors.initials: T
authors.lastname: Ollikainen
authors.forename: A
authors.initials: A
authors.lastname: Knuuttila
authors.forename: S
authors.initials: S
authors.lastname: Suhonen
authors.forename: M
authors.initials: M
authors.lastname: Taavitsainen
authors.forename: A
authors.initials: A
authors.lastname: Jekunen
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: K
authors.initials: K
authors.lastname: Linnainmaa
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D002461:Cell Line, Transformed; D002470:Cell Survival / Q000187:drug effects; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D000077143:Docetaxel; D004847:Epithelial Cells / Q000187:drug effects*; D006801:Humans; D000077146:Irinotecan; D008654:Mesothelioma / Q000188:drug therapy / Q000378:metabolism*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000494:pharmacology; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D000093542:Gemcitabine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D003841:Deoxycytidine; D000077143:Docetaxel; D000077146:Irinotecan; D017239:Paclitaxel; D002166:Camptothecin; D000093542:Gemcitabine